Results of the MPACT Trial (weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone) in patients with metastatic pancreatic cancer will be reviewed, with emphasis on patient selection and neuropathy management.
The webinar was delivered by Dr. Malcolm Moore, Program Head, Medical Oncology and Hematology, Director, McCain Centre for Pancreatic Cancer; Professor, Department of Medicine and Pharmacology, University of Toronto.
Advertisement